Skip to main content

MoneyWorks4Me

Glenmark Pharmaceuticals submits media release

17 Sep 2019 Evaluate

Glenmark Pharmaceuticals has informed about submission of media release titled ‘Glenmark Receives Orphan Drug Designation for GBR 1342, a Bispecific Antibody Candidate Under Evaluation for the Treatment of Multiple Myeloma’, which is self explanatory.  

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1758.50
Dr. Reddys Labs. 1342.30
Cipla 1360.50
Lupin 1987.90
Zydus Lifesciences 1178.95
View more..